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Breast cancer is the leading cause of cancer deaths among females globally. Although 
localized or early stage cancer is largely curable, the five-year survival rate significantly decreases 
after metastasis. The crosstalk between tumor microenvironment and neoplastic cells is the key for 
promoting tumor growth and stimulating tumor angiogenesis and metastasis to distant organs. In 
the first section of this study, the effect of stromal stiffening on the angiogenic activity of cancer 
cells was explored. Highly aggressive breast cancer cells, MDA-MB-231, displayed an increased 
expression of pro-angiogenesis-related signals when encapsulated in stiffer collagen matrices. In 
comparison, less-invasive cells, MCF-7, showed a minimal change in the release of angiogenic 
signals when cultured on stiffer matrices. Inhibition of mechanotransduction pathways on the 
angiogenic activity of aggressive tumor cells in stiff matrices was investigated using Y-27632, 
Blebbistatin, and Cytochalasin D. Rho associated kinase (ROCK) inhibitor, Y-27632, diminished 
the pro-angiogenic signal release, thereby suggesting the potential dependence of breast cancer 
cells on the Rho/ROCK pathway in regulating tumor angiogenesis. 
Breast cancer cells most commonly metastasize to lungs, liver, and brain, with preferential 
metastasis to bone tissue. Initial stages of bone metastasis are not well understood, but studies 
suggest that the host microenvironment is manipulated into allowing the tumor cells to invade and 
proliferate at bone sites. In the second section of this study, the effect of microenvironment on 
bone metastasis was studied. Mesenchymal stem cells (MSCs) were differentiated into osteoblasts, 
and the deposited matrices were decellularized. The key components of the deposited extracellular 
matrix (ECM) were characterized. Furthermore, the effect of the decellularized ECM (dECM) on 
xi 
 
the activity of breast cancer cells was investigated. In the presence of dECM, MDA-MB-231 cell 
proliferation increased, and the efficacy of anti-cancer drug, 5-fluorouracil, on the cancer cells was 
reduced.   
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Chapter 1: Introduction 
More than 2,300 years ago, Hippocrates likened the long, enlarged veins protruding from 
breast tumors to the legs of a crab leading him to come up with the Greek term karkinoma, or the 
now more common Latin term, cancer [1]. It was not until after the work of Robert Hooke in the 
1600s, with the discovery of the cell, and Rudolf Virchow in the 1800s, who recognized that 
diseases arose in the cells, that cancer would be understood as a disease of uncontrolled cell 
division [1]. Today, cancer is a term that refers to over 100 disease types; although similar in the 
general processes of the disease, each type is characterized by its own unique properties such as 
cause, location in the body, and invasiveness [1]. This study explores how the cellular environment 
affects the progression of tumors. To this end, it is important to understand how tumors develop 
by first understanding how cancerous cells are different from normal, healthy cells, how these 
differences arise, and what they entail in terms of cell behavior and disease.  
A normal cell is restricted in its ability to grow and divide by specific genes that control a 
sequence of events, known as the cell cycle [1]. These genes can be categorized into two groups; 
one category referring to genes that promote cell division, known as proto-oncogenes, and another 
category that inhibits cell division, known as tumor suppressor genes [1]. In normal cells, these 
two categories regulate cell growth in an effort to maintain the size and structure of each tissue in 
the body. The balance in the expression of these two types of genes is dependent on several intra- 
and inter-cellular signals such as the concentration and type of growth factors present in the cell 
environment, as well as the cell-cell communication that results in contact inhibition [1]. 
Furthermore, normal cells are limited by the number of times they divide before they reach 
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senescence, a concept known as the Hayflick limit, after Leonard Hayflick, due to the shortening 
of the telomeres, or the ends of chromosomes, that occurs with each cell division [2].  
Unlike normal cells, cancer cells have uncontrolled cell replication, which means that they 
have lost the restrictions that inhibit cell growth [1]. This loss is due to the mutations that occur in 
both the proto-oncogenes and the tumor suppressor genes. Mutated proto-oncogenes, or 
oncogenes, induce excessive cell growth by causing an increased expression of growth factors, by 
producing receptor proteins that release growth-promoting signals to the inside of the cell, or by 
disrupting the signaling pathway inside the cell such that the nucleus receives endless stimulatory 
signals[1, 3]. These mutations are responsible for the cancer cells’ ability to grow despite the 
absence or reduced concentration of growth factors in their environment [1, 3]. Mutated tumor 
suppressor genes prevent the inhibition of cell division as they no longer prevent the flow of 
growth-related signals, or they no longer produce active proteins that are an integral part of certain 
inhibitory pathways within the cells. These mutations also provide cancerous cells with a key 
characteristic in which they do not exhibit contact inhibition, a process of halting cell division 
when cells come in contact with each other [1]. Additionally, mutations in other genes, such as 
DNA repair genes, prevent the cell’s ability to repair DNA errors during replication, causing more 
frequent mutations than normal, some of which affect proto-oncogenes and tumor suppressor 
genes. Furthermore, cancer cells have the ability to divide indefinitely and, unlike normal cells, do 
not reach senescence due to the presence of the enzyme, telomerase, which replaces telomeric 
fragments that are clipped with each cell division [1, 3]. They also evade a key cellular defense 
mechanism known as apoptosis, in which diseased or injured cells undergo a programmed death 
[3]. The cell’s ability to avoid this suicidal death, often through the inactivation of the p53 protein 
due to tumor suppressor gene mutations, contributes to the uncontrolled growth of tumor cells as 
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well as their resistance to chemotherapy or radiation treatment that would usually induce cell death 
by damaging the cell’s DNA [1].  
While the cause of these mutations has been linked to aging, exposure to carcinogens, and 
genetic susceptibility, current understanding of the development of cancer suggests that it is a 
multistep process that occurs over a long period of time [1]. The exact number of mutations 
required for a normal cell to transform into a cancerous one is not known. However, the stages of 
tumor development begin when enough mutations occur to disrupt the regulated growth of the cell 
[3]. The transformed cell and its daughter cells divide continuously, resulting in tissue enlargement 
or hyperplasia, an initial stage of cancer [3]. Eventually, one or a few of the dividing daughter cells 
might undergo another mutation, not only resulting in excessive division but also a different 
morphology, another stage of tumor development called dysplasia [3]. This phenomenon explains 
why although cancer cells within the same tumor type are monoclonal, individual cells may have 
different characteristics. A localized tumor that remains within the same tissue of origin is called 
in situ cancer and can remain within the same tissue for an indefinite period [1]. However, 
additional mutations that occur in some cells may cause the tumor to gain new abilities and 
characteristics, such as its ability to detach from the primary tumor and migrate to nearby tissues 
or distant organs if they gain access to the bloodstream [1]. In this case, the tumor becomes 
malignant and is called invasive cancer.  
Regardless of the type of cancer, all solid tumors require an adequate supply of oxygen and 
nutrients and a means of byproduct or waste removal [4]. In fact, the ability of any tissue to grow 
beyond a certain size cannot merely rely on the passive diffusion of oxygen and nutrients due to 
the limitations it has on molecular transport over distance and time. The design of the 
cardiovascular system in the body ensures that there is enough blood flowing through the blood 
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vessels, or capillaries, that surround tissues and cells [5]. Tumors are no different than normal 
tissues in that regard. Tumor angiogenesis is the process by which blood vessels form and penetrate 
the cancer environment. This process is activated in response to hypoxia, where the cells in the 
tissue become oxygen deprived due to the high division rate of the tumor cells. When hypoxia is 
combined with a shortage of nutrients, the cells express various inflammatory signals that recruit 
vascular cells to form blood vessels at the tumor site [4]. Blood vessels are comprised of a 
monolayer of endothelial cells that form the inner lumen and stabilizing pericytes and vascular 
smooth muscle cells that form the exterior. Neovascularization, or the formation of new blood 
vessels, involves two mechanisms, vasculogenesis and sprouting angiogenesis [4]. Vasculogenesis 
is the formation of new blood vessels through the differentiation of vascular progenitor cells, while 
angiogenesis involves the formation of new blood vessels from preexisting blood vessels [6]. Of 
the two mechanisms, the latter is one of the most studied and understood process used by cancer 
cells to induce the formation of their own capillaries.  
Sprouting angiogenesis begins with the destabilization of the basement lamina around 
endothelial cells, followed by the endothelial-mesenchymal conversion in which endothelial cells 
exhibit increased proliferation and migration from the original vessel into the connective tissue 
[7]. The new endothelial cells are connected to each other and to cells of the mother vessel through 
intercellular junctions so that the two lumens remain connected. Once the endothelial cells have 
formed an immature blood vessel, the process of vessel maturation begins. For this to occur, a 
reverse mesenchymal-endothelial conversion causes endothelial cells to return to their dormant 
state so that they do not continue to proliferate and migrate [8]. Furthermore, pericytes and vascular 
smooth muscle cells are recruited, and a new basement lamina is formed [8]. The steps involved 
in the development of these new blood vessels are guided by different stimuli from the tumor cells, 
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known as pro-angiogenic signals [4], resulting in a sustained angiogenic process that generates 
heavy vasculature to support the growing tumor, no different from the distended blood vessels of 
breast tumors that Hippocrates compared to crab limbs many centuries ago.  
The selectivity for metastasis to specific sites is determined by the cancer cells’ ability to 
complete the steps of the metastatic cascade. In order for metastasis to occur, cancer cells must 
first detach from the primary tumor, intravasate blood vessels, evade the immune system, and 
attach at new distant organs and proliferate resulting in the establishment of secondary tumors [9].   
Certain metastatic cells prefer to grow in specific organs. In breast cancer, for example, metastasis 
affects the lungs, bones, liver, and brain, with bone being the preferred site [10]. Anatomical effects 
such as proximity and easy access to certain sites, as well as mechanical effects, such as blood 
flow, influence the location of metastasis [11]. However, it is the microenvironment that ultimately 
determines which metastatic site is favored and promotes tumor growth at that location. Tumor 
cells manipulate the host microenvironment by sending signals in the form of biochemical factors 
from the primary tumor site, adhering to endothelial cells at distant sites, and invading and 
colonizing the target site [12]. 
  As a major component of tumor and host microenvironment, the extracellular matrix 
(ECM), a complex network of proteins and other macromolecules with specific biochemical and 
mechanical properties, plays an important role in tumor progression and metastasis [13-14]. The 
properties of the ECM determine the cell’s ability to detect and respond to external stimuli, thereby 
regulating cell behavior and contributing to tumor progression [15]. The work in this thesis is 
divided into two sections. Part 1 will focus on investigating the effect of matrix stiffening on 





















Chapter 2: Motivation and Objectives 
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death 
among females worldwide [16]. When diagnosed early or at a localized stage, the five-year 
survival rate increases to 98% as compared to a 27% survival rate after metastases [17].  When 
tumors begin to grow beyond 1-2 mm3, the diffusion of nutrients and oxygen into the native tissue 
becomes insufficient to support the insatiable metabolic demands required for the continued 
growth and survival of the tumor cells [18]. Consequently, the cells release a combination of 
angiogenic factors to recruit endothelial cells from neighboring blood vessels and induce the 
formation of new blood capillaries, not only to provide the cells with the necessary oxygen and 
nourishment required for the cells’ continued growth, but also to provide an avenue through which 
these cells can migrate and reach distant organs in the body [19]. Therefore, angiogenesis, i.e. the 
formation of blood vessels from pre-existing vessels, becomes the rate-limiting step for tumors to 
grow and metastasize [20]. Specifically, a change in the balance between regulatory pro- and anti- 
angiogenic factors, leading to the increase in the net stimulatory activity and the onset of 
angiogenesis, triggers metastatic tumor growth [21].  
Recent inquiries into tumor progression allude to the importance of microenvironmental 
biophysical cues in stimulating the aggressive phenotype of cancer cells [13-14]. As a major 
component of tumor microenvironment, extracellular matrix (ECM) is believed to play an 
important role in tumor development and metastasis [13-14]. The ECM is a complex network 
consisting of distinct macromolecules which result in a matrix with specific physical, biochemical, 
and mechanical properties [22]. Together, these properties provide the structural support for the 
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cellular components of tissues and pertain to the signaling mechanisms that determine the cell’s 
ability to sense and react to external mechanical forces, thereby actively regulating cell behavior 
and contributing to tumor progression [15, 22, 23, 24].  Type I and IV collagen proteins are the 
most prevalent components of the ECM providing the main structural support for the interstitial 
matrix and the key component of the basement membrane, respectively [25-27]. Typically, tumor 
tissue is stiffer than healthy tissue owing to the continuous remodeling of the ECM, due to elevated 
production, deposition, and altered organization of collagen and related macromolecules, in 
tandem with increased metalloproteinase (MMP) activity [24]. Cancer cells recognize the increase 
in matrix stiffness and respond by generating increased traction forces on their surroundings 
through actomyosin and cytoskeleton contractility [28]. This increased stiffness leads to a series 
of signaling cascades that regulate gene expression and result in enhanced cancer cell growth and 
migration and contribute to the invasive phenotype, commonly associated with tumors [29]. 
However, despite the importance of tumor stroma stiffening and the centrality of 
vascularization in tumor progression, how the mechanical forces are co-opted in the cancer cell 
signal transduction pathways, and, ultimately, in the angiogenic response of the cancer cells 
remains unclear. We demonstrated in our previous studies, using mechanically tuned hydrogels, 
that the matrix stiffening of the highly aggressive breast cancer cell line, MDA-MB-231, not only 
promotes cell proliferation and migration, but it also correlates with higher levels of VEGF 
expression, indicating stimulated angiogenic activity by the cells [30]. Furthermore, inhibition of 
actomyosin organization reduced VEGF secretion by the cancer cells [30]. Another recent study 
has reported upregulated VEGF expression by hepatocellular carcinoma (HCC) cells when 
cultured on stiffer matrices [31]. Together, these studies suggest the potential existence of a 
regulatory mechanotransduction pathway that may govern the angiogenic activity of tumor cells.  
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We hypothesize that ECM stiffening during tumor progression regulates the pro-
angiogenic signaling of cancer cells and interruptions in the mechanotransductive pathway may 
have a therapeutic potential in disrupting vascularization and slowing tumor progression. 
Therefore, this work is aimed at understanding how changes in the mechanical properties of tumor 
microenvironment influence the angiogenesis signaling by cancer cells. The research conducted 
in this study addressed the following four objectives, which will be explored more deeply in the 
upcoming chapters. 
Objective 1: Develop and characterize 3D scaffolds of varying stiffness. Three dimensional 
scaffolds with different compliances were fabricated from collagen protein and 
characterized for their stability, swelling, microstructures, and macromolecular diffusion. 
Objective 2: Explore the effect of matrix stiffness on signaling profile of aggressive breast 
cancer cells. MDA-MB-231 cells were encapsulated in the gels of varying stiffness. Their 
proliferation, morphology, and the release of angiogenic factors as a function of matrix 
mechanics was examined. The bioactivity of the released biomolecules was also assessed 
through the proliferation activity of human umbilical vein endothelial cells (HUVECs). 
Objective 3: Explore the effect of matrix stiffness on the signaling profile of non-aggressive 
breast cancer cells. MCF-7 cells were encapsulated in the gels of varying stiffness. Their 
proliferation, morphology, and the release of angiogenic factors was studied.  
Objective 4: Test the effect of mechanotransduction inhibitors on the angiogenic activity 
of cancer cells. Inhibitors targeting the mechanotransduction pathway were added to 
aggressive breast cancer cells encapsulated in stiff matrices. Their effect on the signals 
released by the cells was studied.  
10 
 
Chapter 3: Fabrication and Characterization of Collagen Hydrogels 
Introduction 
Hydrogels are three dimensional networks of crosslinked hydrophilic polymer chains, 
named for their ability to retain significant amounts of water. This ability to absorb water, along 
with their other characteristics, such as biocompatibility, porosity, and tunable mechanical strength 
and biodegradability suggests their potential applications in tissue engineering [32]. Hydrogels can 
be fabricated from either natural or synthetic polymers. Synthetic polymers are usually chosen 
over natural hydrogels due to their longer service life, higher capacity of water absorption, and a 
greater mechanical strength [32]. Nonetheless, hydrogels made from naturally derived polymers 
are sometimes preferred in certain applications due to their composition and fiber organization that 
contributes to their ability to more closely mimic the extracellular matrix (ECM) [33].  
Hydrogels made from collagen are one of the most popular and have been used to study 
“soft” tissues such as the skin, cartilage, and vascular structures [34]. The preference of collagen 
in tissue engineering application arises from it being one of the major components of the ECM 
[33]. However, applications of collagen hydrogels are limited due to their high compliance and 
low ability to retain their shape. To solve this problem, collagen gels are processed by the addition 
of various crosslinkers and exposure to different treatments that increase the mechanical strength 
of the scaffolds while simultaneously making them cytotoxic or inappropriate for cross linking in 
the presence of cells [34]. For this reason, other methods have been developed to promote collagen 
crosslinking and increase mechanical strength, thereof. One such method is non-enzymatic 
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glycation of collagen with reducing sugars, such as ribose or glucose, which allows cross-linking 
of cell-seeded collagen structures [34]. 
Non-enzymatic glycation is carried out through the Maillard reaction, where the aldehyde 
group on reducing sugars reacts with amino groups on collagen. The reaction produces a Schiff 
base which forms Amadori products that eventually form glycation end products. The 
accumulation of these end products in tissues results in a change in their mechanical and 
biochemical properties, as observed in conditions such as aging and diabetes [34]. Due to the 
ability to achieve this change in mechanical properties, a non-enzymatic pre-glycation approach 
was used to fabricate collagen gels of varying stiffness.  
To ensure that these mechanically tuned hydrogels were stable and would retain their 
shape, the rate of degradation was measured. Furthermore, the degree of swelling was also studied, 
and their internal microstructure was examined. Since the goal of this study is to understand how 
cell angiogenic activity is affected in environments of different stiffness, it was important to ensure 
that the collagen gels would allow the diffusion of nutrients and oxygen molecules into the gel and 
waste products and released signals out of the gel to be profiled. For this reason, the diffusion 
kinetics of the collagen constructs were considered.  
Methods 
Fabrication of Collagen Gels 
To fabricate mechanically tunable gels without altering the protein concentration, non-
enzymatic pre-glycation of collagen, known as Maillard reaction, was carried out as described 
earlier [34]. Briefly, rat tail high concentration collagen type I solutions (Corning, MA) were 
mixed with 500 mM ribose (Thermofisher Scientific, MA) to form glycated collagen solutions 
with a final concentration of 0, 50, 100, 200, and 250 mM ribose in 0.02N acetic acid (Fisher 
Chemical, NJ) and incubated for 5 days at 4℃ [34]. Following pre-glycation, collagen gels were 
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fabricated according to the manufacturer’s protocol. Briefly, glycated collagen solutions were 
neutralized with 1M sodium hydroxide (NaOH, Sigma Aldrich, MO) in 10X Dulbecco’s 
Phosphate Buffer Saline (DPBS, Gibco, NY) and diluted with distilled water. Collagen gels were 
formed by adding 250 µL of the neutralized solution to the wells of a 48-well plate and allowed to 
cross-link for 30 minutes in an incubator at 37℃ to form gels with a final collagen concentration 
of 1.5 mg/mL. 
Degradation 
To measure the rate of collagen gel degradation, the samples were incubated in 2.5 
units/mL collagenase type I (Gibco, NY) solution on a rotator shaker at room temperature. The 
weights of the gels were measured each day for 10 days, consecutively. The degradation ratio was 
calculated by normalizing the weights of the samples at each day to the weights of the samples on 
the day of fabrication. 
Swelling Ratio 
To measure the swelling ratio (Qm) of the collagen gels, the samples were incubated in 
DPBS for 72 hours on a rotator shaker at room temperature following gel formation. The wet 
weights of the hydrated gels were measured. The hydrogels were then dried at 37℃ overnight, and 
their dry weights were measured. The swelling ratio of the hydrogels was then calculated as a ratio 
of wet weights to dry weights.  
Diffusion 
To measure the rate of diffusion of macromolecules from the gels, fluorescein 
isothiocyanate-dextran (FITC-dextran) molecules of 150K MW (Sigma Aldrich, MO) were added 
to the neutralized collagen gel solution at a concentration of 50 µg/mL (w/v), and the collagen gels 
were fabricated after incubation for 30 min at 37℃. The gels were washed and incubated in DPBS 
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for seven days. Each day, the buffer solution containing the diffused molecules was collected and 
replaced with 500 µL of fresh DPBS.  The fluorescence intensity for each sample was measured 
using SpectraMax M3 Multi-Mode Microplate Reader at excitation/emission wavelengths 495/519 
nm. The diffusive release was calculated as a percentage using the following equation: 
 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 (%) = 100 × 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑒𝑥𝑡𝑟𝑎𝑛 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑒𝑎𝑐ℎ 𝑑𝑎𝑦 (𝑔)
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑒𝑥𝑡𝑟𝑎𝑛 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑔𝑒𝑙 𝑎𝑓𝑡𝑒𝑟 𝑤𝑎𝑠ℎ (𝑔)
 
To determine the mechanism of macromolecule release through the collagen gels, the following 




= 𝑘𝑡𝑛  
where F is the fractional release of the molecule, Mt is the amount of dextran diffused at any time, 
M0 is the total initial amount of dextran that was encapsulated within the gels, k is the kinetic 
constant, t is time, and n is the diffusional exponent. Where n ≤ 0.5, the transport of 
macromolecules can be defined by Fick’s diffusion alone. Where 0.5 > n ≤ 0.9, the transport of 
molecules is governed by both diffusion and polymer relaxation/erosion, and for n > 0.9, polymer 




At least three independent experiments were performed with five replicates per experiment. 
Scanning Electron Microscope 
Collagen gels were fabricated and left to dry overnight at 50℃. The dried samples were 
subjected to gold sputtering for 7 seconds. Images of the collagen fibers and pores were then 
captured using Zeiss scanning electron microscope (LEO 1455 VP).  
Results and Discussion 
The mechanical properties of the collagen hydrogels were altered via non-enzymatic pre-
glycation in which the concentration of ribose was varied from 0 mM to 250 mM, while the 
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concentration of collagen was kept constant at 1.5 mg/mL. Mason and coworkers showed that an 
increase in ribose concentration resulted in an increase in mechanical stiffness of the hydrogels as 
demonstrated by a fourfold increase in compressive modulus from approximately 175 Pa to 730 
Pa [35]. In this study, the integrity of the collagen gels was assessed by measuring enzymatic 
degradation profiles in the presence of collagenase. Over the 10-day period, a decrease in the 
normalized weights of the gels was observed, irrespective of ribose treatment (Fig 1). This 
decrease in weights corresponded to their degradation in presence of collagenase. All the gels 
retained their physical integrity over the course of the 10 days, indicating no effect of pre-glycation 
on the degradation of the gels (p-value > 0.05). Since, the goal of this study is to investigate the 
effect of matrix stiffness on cancer cell behavior, the collagen gels with the lowest and highest 
compression moduli were selected for further studies. 
 
Figure 1. Degradation of pre-glycated (0 mM, 50 mM, 100 mM, 200 mM, and 250 mM ribose) collagen gels 
monitored over 10 days. Error bar S.E.M (N=3). 
The effect of pre-glycation treatment on the swelling ratio of the collagen gels was also 
investigated. As shown in Table 1, the swelling ratio of the gels decreased from 73.8 ± 10.9 
(collagen gels without ribose treatment) to 49.6 ± 6.5 (collagen treated with 250 mM ribose). In 
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microscopy. The ribose treatment and the consequent change in mechanical properties did not alter 
the organization of collagen fiber structures (Fig 2).  
Table 1. Comparison of swelling ratio and diffusional exponent  of hydrogels as a function of ribose concentration 
Ribose Concentration Swelling Ratio Diffusion Exponent 
0 mM 73.7513 ± 10.8857 0.567838 ± 0.030944 
250 mM 49.5730 ± 6.4934 0.627931 ± 0.008974 
 
                  
Figure 2. Scanning electron microscope images of collagen network. 
To assess whether non-enzymatic pre-glycation altered the free volume available for 
transport of macromolecules across the hydrogels, the macromolecular release kinetics was 
investigated. For this purpose, collagen disks (with or without incubation with 250 mM ribose) 
were fabricated encapsulating FITC-conjugated (150kDa) dextran. Figure 3 compares the 
cumulative release (% released) of dextran over a span of 7 days. No significant difference in 
release kinetics of macromolecules from the collagen gels was observed as a function of ribose 
treatment. To investigate the release mechanism, the fractional release data was fitted into 
Korsemeyer-Peppas equation and the fitting parameters were calculated.  The average values of 
0 mM 250 mM 
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diffusional exponent (n) for the collagen gels were found to be greater than 0.5, but less than 0.9 
(Table 1), thereby suggesting that the transport of macromolecules across the gels is via, both, 
Fickian diffusion as well as polymer relaxation/erosion.  
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Chapter 4: Effect of Matrix Stiffness on Aggressive Breast Cancer Cell Behavior 
Introduction 
The stroma of cancerous breast tissue becomes 5-20 times stiffer than that of normal breast 
tissue [36]. This stiffness is due to a change in the tumor microenvironment through an increased 
deposition of collagen and/or its reorganization. This change in the structure and, ultimately, the 
properties of the ECM affects mammary epithelial cell shape, enhances cell growth, encourages 
cell invasion, and, overall, contributes to tumor development [24]. Recent studies have highlighted 
the role of the ECM and its components on tumor vascularization, a necessary and key 
characteristic of tumor cells. One such example involves integrin clustering, a key transmembrane 
protein that allows cell-ECM adhesion, which was shown to upregulate the expression of vascular 
endothelial growth factor (VEGF) by cancer cells, an important promoter of angiogenesis [37]. 
Although it is already established that the increased stiffness has a major effect on the 
behavior of cancer cells, not much is understood about how this change in stiffness affects tumor 
angiogenesis, especially in malignant cancers. A previous study found that aggressive breast 
cancer cells, not only exhibited an increase in proliferation and motility when seeded on rigid 
matrices, but also stimulated the expression of VEGF [30]. This suggests that the increased rigidity 
of the tumor microenvironment plays a regulatory role in angiogenic signaling of cancer cells. 
Here, the impact of stiffness on the angiogenesis release by malignant tumor cells is explored in 
depth by analyzing the secretion levels of pro- and anti-angiogenic factors released into the 
medium by the cells. For this purpose, MDA-MB-231 cells, which were isolated and expanded 
from a patient with invasive ductal carcinoma, were used. The cells were encapsulated in collagen 
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hydrogels, and their angiogenic signaling was profiled using a human angiogenesis antibody assay. 
Furthermore, the bioactivity of the released signals was studied by testing the proliferation of 
human umbilical vein endothelial cells (HUVECs).  
Methods 
Cell Culture 
Highly invasive breast cancer cells (MDA-MB-231) and low invasive breast cancer cells 
(MCF-7) were purchased from American Type Culture Collection (ATCC) and expanded in RPMI 
1640 Medium and Dulbecco’s Modified Eagle Medium (DMEM), respectively; each 
supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin-streptomycin. 
Human umbilical vein endothelial cells (HUVECs) were obtained from (ATCC) and expanded in 
endothelial cell nasal medium-2 (EBM-2) supplemented with 1% (v/v) penicillin-streptomycin and 
EGM-2 Single Quots (containing FBS, hydrocortisone, hFGF, VEGF, R3-IGF-1, ascorbic acid, 
hEGF, GA-100, and heparin). Cells were cultured and incubated at 37℃ and 5% CO2. In this 
study, MDA-MB-231 cells were used up to passage 7. HUVECs were used up to passage 6. 
Cell Proliferation 
Following detachment from the flasks using 0.25% Trypsin-EDTA, resuspended MDA-
MB-231 cells were incorporated into the collagen gels by adding the cells to neutralized collagen 
solutions at a density of 12.5 x 104 cells/gel and incubated in 300 µL of serum-free media at 37 ℃ 
and 5% CO2 after gel formation. Collagen gels were collected and frozen immediately after gels 
were formed, and again after 2, 4, and 6 days. The collected samples were digested with papain 
solution at 37 ℃ for 3 hours. The papain solution was created by dissolving 0.1M sodium acetate, 
0.01M Na2EDTA, and 0.005M cysteine hydrochloride in 0.2M sodium phosphate buffer and 
adding papain suspension (Sigma-Aldrich, MO). Cell proliferation was assessed using Quant-iT™ 
dsDNA High-Sensitivity Assay Kit (Thermo Fisher, USA). The fluorescence intensity was then 
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measured using SpectraMax M3 Multi-Mode Microplate Reader at excitation/emission 
wavelengths 480/530 nm. Cell proliferation over time was calculated as a percentage by dividing 
the fluorescence intensity of the gels at each day over the day of fabrication using the following 
equation: 




The data was collected from at least three-independent experiments, each of which was carried out 
in three replicates. 
Immunostaining 
MDA-MB-231 cells incorporated into collagen gels at a cell density of 2.5 x 104 cells/gel 
were stained with 1% (v/v) Hoechst 33342 dye for 5 min. The cells were then fixed and 
permeabilized with 1:1 acetone:methanol solution at -20℃ for 20 min. The cells were then blocked 
with 5% (w/v) BSA solution for 1 h, washed with 1X DPBS three times, and incubated with 2.5% 
(v/v) Alexa Fluor 488-phalloidin antibody for 1 h at 37℃. Following which, the cells were washed 
three times with 1X DPBS, and images were captured using Olympus laser scanning confocal 
microscope (FV 1200) to visualize the actin arrangement of the cell. 
Quantification of Released Angiogenic-related Factors 
To quantify the release of angiogenic factors by highly aggressive breast cancer cells as a 
function of microenvironment, MDA-MB-231 cells were encapsulated within collagen gels at a 
density of 12.5 x 104 cells/gel in 48 well plates and incubated in serum-free media. Four days post-
fabrication, the spent media was collected and concentrated using Vivaspin 2 (2000 MWCO) 
centrifugal concentrators. Angiogenic molecules in the media were measured via Proteome 
ProfilerTM Human Angiogenesis Array from R&D Systems. Bio-Rad Molecular Imager with 
ChemiDoc XRS+ Imaging System was used to image the membranes, and the average intensity of 
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each angiogenic factor was measured using the Image Lab Software (Version 4.1).  The 
angiogenesis array was run two times. 
Proliferation of HUVECs  
HUVECs were seeded in 96 well at a density of 1 x 104 cells/well and incubated in the 
presence of concentrated media (collected from encapsulated cancer cells after 4 days) containing 
released angiogenic factors at 37℃ and 5% CO2. Cells incubated in endothelial cell growth media 
and serum-free RPMI media served as the positive and negative controls, respectively. After 48 h 
of incubation, AlamarBlue cell viability reagent was added to fresh media and allowed to incubate 
for 3.5 h at 37℃ and 5% CO2 and the fluorescence intensity was then measured using SpectraMax 
M3 Multi-Mode Microplate Reader at excitation/emission wavelengths 570/595 nm. Cell growth 
was then calculated as a percentage using the equation below: 





The data was collected from at least three independent experiments with three replicates per 
experiment. 
Results 
To study the impact of ECM stiffening on cellular behavior, highly invasive breast cancer 
cells (MDA-MB-231) were encapsulated within collagen gels of varying stiffness. Towards this 
goal, 5 x 104 cells/mL were suspended within collagen solution. 250 µL of the solution was then 
added in the wells of 48-wellplates and incubated at 37℃ and 5% CO2 for 30 minutes. DNA 
quantification was used to assess the cell viability of the cells 2, 4, and 6 days post encapsulation. 
When MDA-MB-231 cells were encapsulated within the compliant gels (Fig 4), a significant 
increase in cell growth was observed compared to day 0 (p-value < 0.05).  Moreover, it was 
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observed that beyond day 4, the increase in cell growth was not statistically different (p-value > 
0.05). On the other hand, when encapsulated within the stiffer collagen gels, a subtle increase in 
growth of MDA-MB-231 cells was observed on day 2 compared to day 0 (p-value < 0.05). When 
cultured for longer period of time, no difference in cell growth was observed compared to day 2 
(p-value > 0.05).   
                       
Figure 4. Proliferation of MDA-MB-231 cells encapsulated in glycated (250 mM) and non-glycated (0 mM) gels. 
Cell growth was assessed after 2, 4, and 6 days and compared to the day of fabrication. Error bar S.E.M (N=3). (*p-
value<0.05 in comparison to day 0). 
Four days post-fabrication, the F-actin cytoskeleton of the cells was stained by Alexa Fluor 
488 conjugated phalloidin antibody and the confocal images of the cells were captured. As 
demonstrated in Fig 5, while MDA-MB-231 cells displayed stress fiber formation irrespective of 
matrix stiffness; however, manifestation of invadopodia, actin-based protrusion of the plasma 



































      
Figure 5. The confocal images of MDA-MB-231 cells in (A) soft and (B) stiff collagen gels displaying the 
arrangement of actin fibers (green). Hoechst 33342 (blue) stained the nuclei of the cells. The scale bar corresponds to 
50 µm. 
To investigate how matrix mechanics influences the release of angiogenic factors by the 
cancer cells, four days post-fabrication, the serum-free conditioned media was collected, and the 
angiogenic molecules were measured via Proteome Profiler Human Angiogenesis. The release of 
pro-angiogenic molecules by MDA-MB-231 cells encapsulated within collagen gels treated with 
250 mM ribose (730 Pa) was compared with those encapsulated with collagen gels without 
treatment with ribose (0 mM, 175 Pa) (Fig 6A). As observed, stiffer gels stimulated angiogenic 
signaling of the cancer cells as manifested from enhanced secretion of pro-angiogenesis related 
factors. In addition, multiple pro-angiogenesis factors including angiogenin, angiopoietin-1, 
CXCL16, EGF, EG-VEGF, endoglin, FGF acidic, FGF basic, FGF-4, FGF-7, HGF, leptin, MCP-
1, MMP-8, PDGF-AA, PDGF-AB/PDGF-BB, PIGF, VEGF-C were released only when the cells 
were encapsulated within stiffer gels. On the other hand, comparison of secretion of anti-
angiogenic molecules revealed no drastic difference in the secretory signatures of cancer cells 
when matrix stiffness was altered (Fig 6B). Few anti-angiogenesis factors including ADAMTS-1, 
angiostatin/plasminogen, endostatin/collagen XVIII, platelet factor 4, serpin B5, and vasoinhibin 




were released only by cells encapsulated within the stiffer gels, albeit the expression level was 
very low.  
 
 
Figure 6. Effect of matrix stiffness on angiogenic activity of MDA-MB-231 cells. The mean pixel density of (A) pro-
angiogenic factors and (B) anti-angiogenic factors released by MDA-MB-231 cells encapsulated in compliant (0 mM) 
and stiff (250 mM) collagen gels assayed via Angiogenesis Proteome Profiler. 
Further, for quantitative analysis of angiogenic signaling of MDA-MB-231 cells, the signal 
intensities of the pro-angiogenic factors released by the cells encapsulated within stiffer gels were 
normalized with respect to the compliant gels. The expression levels of multiple pro-angiogenic 
molecules including activin A, amphiregulin, artemin, IL-1β, persephin, uPA, and VEGF were 
upregulated (normalized values > 1.5) (Fig 7A) whereas the expression levels of anti-angiogenic 






Figure 7. The normalized expression of angiogenesis related factors released by MDA-MB-231 encapsulated within 
glycated gels with respect to those released from non-glycated gels. The normalized expression of (A) pro-angiogenic 
factors and (B) anti-angiogenic factors. The closely dashed and widely dashed lines corresponds to the relative 
expression of 0.5 and 1.5, respectively. 
To study the effect of this angiogenic cocktail on the proliferation of endothelial cells, 
conditioned media was collected 4 days post-encapsulation of MDA-MB-231 cells within collagen 
gels. HUVECs were seeded at a density of 1 x 104 cells/well in 96 well plates in the presence of 
conditioned media, and their cell growth was assessed. HUVECs cultured in presence of 
supplemented endothelial cell growth media and serum-free RPMI media acted as the positive and 
negative controls, respectively. To quantitatively assess the effect of conditioned media on growth 
of HUVECs, proliferation of cells was normalized with respect to cells incubated in supplemented 





of conditioned media collected from MDA-MB-231 cells incubated in the stiffer gel. However, 
the increase in growth was insignificant (p-value > 0.05).  
 
Figure 8. Effect of released angiogenic factors on the proliferation of HUVECs. Cell growth in the presence of 
conditioned media collected at Day 4 was normalized with respect to that in presence of HUVECs media (control). 
Error bar S.E.M (N=3). 
Discussion 
Recent studies attempting to better understand the factors influencing tumor progression 
have drawn attention to components of the tumor microenvironment, specifically the ECM. The 
continuous remodeling of the ECM contributes to a stiffer matrix in tumor tissue, thereby 
activating signaling pathways that stimulate tumor progression through increased cell proliferation 
and migration [29]. However, little is known about how this increased stiffness affects the 
signaling pathways that control the angiogenic activity of cancer cells. Breast tissue, considered a 
soft tissue under physiological conditions, stiffens markedly with tumor development leading to 
alteration in the micro-environmental physical forces [38-39]. In this current study, we sought to 
understand how this matrix stiffening alters the pro-angiogenic activity of cancer cells. Towards 
this goal, we developed 3D scaffolds of varying compliances (175 kPa and 730 kPa) using a non-































were encapsulated in the collagen gels, and the angiogenesis-related factors secreted by the cells 
were profiled. The increase in stiffness translated to the expression of multiple pro-angiogenic 
factors that were not expressed by the cells encapsulated in the compliant gels (angiogenin, 
angiopoietin-1, FGF acidic, basic, FGF-4, and FGF-7, PDGF, CXCL16, EGF, EG-VEGF, 
Endoglin, HGF, Leptin, MCP-1, MMP-8, PDGF-AA, PIGF, VEGF-C ) along with an upregulation 
of several pro-angiogenic factors that were expressed in both including activin A, amphiregulin, 
artemin, IL-1β, persephin, uPA, and VEGF. This is consistent with previous studies where MDA-
MB-231 were found to express higher levels of VEGF when seeded on matrices of increased 
stiffness [30]. In tumors, VEGF is secreted by cancer cells and surrounding stroma and contributes 
to tumor progression and invasion, increased blood vessel density, and metastasis [40, 41]. 
Moreover, VEGF and PDGF both play a role in inducing intussusceptive angiogenesis, a process 
found in many cancers including breast cancer [40, 42-43]. The upregulation of MMP (matrix 
metalloproteinase) and uPA (urokinase plasminogen activator) in the stiffer matrices is of key 
significance as it has been shown to modulate VEGF-mediated cell invasion by degrading the basal 
membrane and extracellular matrix and allowing endothelial cells to migrate and form sprouts [40, 
44, 45]. FGF has been shown to not only play a role in tumor angiogenesis, but also have a role in 
initiation or promotion of tumorigenesis [46]. Angiogenin, which was only expressed by cells in 
the stiffer matrix promotes tumoral growth and angiogenesis [47], and angiopoietin-1 stimulates 
vessel maturation and their stabilization [40]. Leptin, the hunger-inhibiting hormone, was also 
expressed only by the cells encapsulated in the stiffer matrix, and studies have highlighted its role 
in breast carcinogenesis as it affects ER signaling and aromatase activity [48-50]. 
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Chapter 5: Effect of Matrix Stiffness on Non-Aggressive Breast Cancer Cell Activity 
Introduction 
 It has been established in earlier chapters that the ECM in tumor microenvironments plays 
an important role in regulating cancer cell behavior and contributes to tumor progression by 
promoting an invasive phenotype of cancer cells. Moreover, previous studies have shown that the 
increased stromal stiffness directly influences the proliferation, migration, and VEGF release of 
invasive cancer cell lines [30]. In chapter 4, it was shown that increase in mechanical strength of 
the microenvironment upregulated the release of pro-angiogenic signals by the highly aggressive, 
highly invasive breast cancer cell line, MDA-MB-231. Previous studies showed that cancer cells 
with non-aggressive/non-invasive phenotype do not exhibit stiffness-dependent changes in cellular 
processes [30]. 
To determine whether the angiogenic release by less aggressive breast cancer cells is 
dependent on stiffness, MCF-7 cells were encapsulated in soft and stiff collagen gels for 6 days, 
and their behavior was studied. Their proliferation was tested via DNA quantification over time, 
and their morphology was examined by confocal imaging. Furthermore, the angiogenesis related 
molecules released into the culture medium were profiled using the human angiogenesis antibody 
assay, and the expression of pro- and anti-angiogenic molecules was compared as a function of 
matrix stiffness. 
Results 
To study the impact of matrix stiffening on cells of non-aggressive phenotype, MCF-7 cells 
were incorporated into collagen gels of varying stiffness. DNA quantification was used to assess 
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the viability of the cells 2, 4, and 6 days post-fabrication. As shown in Figure 9, cell viability did 
not change despite the change in matrix stiffness. Further, staining F-actin filaments did not reveal 
any difference in the cytoskeletal organization as a function of matrix stiffness (Fig 10).  
 
Figure 9. Proliferation of MCF-7 cells encapsulated in glycated (250 mM) and non-glycated (0 mM) gels. Cell growth 
was assessed after 2, 4, and 6 days and compared to the day of fabrication. Error bar S.E.M (N=3). 
 
.   
Figure 10.  The confocal images of MCF-7 cells in (A) soft and (B) stiff collagen gels displaying the arrangement of 
actin fibers (green). Hoechst 33342 (blue) stained the nuclei of the cells. The scale bar corresponds to 50 µm. 
To investigate the influence of matrix stiffening on the angiogenic activity of MCF-7 cells, 
4 days post-fabrication, the conditioned media was collected, and the released angiogenic factors 
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collagen gels treated with 250 mM ribose (730 Pa) was compared with those encapsulated with 
collagen gels without treatment with ribose (0 mM, 175 Pa) (Fig 11A). As observed, the expression 
of most pro-angiogenesis related factors was unchanged between the stiffer, ribose treated (250 
mM, 730 Pa) and soft, untreated (0 mM, 175 Pa) gels with the exception of  a few factors (EGF 
and FGF-7) that were only expressed in the compliant gel and VEGF-C which was only expressed 
in the stiffer gel. Similarly, the expression of most of the anti-angiogenic factors from the cells in 
both stiff and compliant gels was unchanged with the exception of endostatin/collagen XVIII 
which was only expressed in the compliant gel and platelet factor 4 and vasoinhibin which were 




Figure 11. Effect of matrix stiffness on angiogenic activity of MCF-7 cells. The mean pixel density of (A) pro-
angiogenic factors and (B) anti-angiogenic factors released by MCF-7 cells encapsulated in compliant (0 mM) and 





Figure 12A and 12B demonstrate the relative expression of the released factors from the 
stiffer gel compared to the compliant gel. No difference in the expression pattern of most of the 
pro- as well as anti-angiogenic molecules was observed (0.5< normalized values <1.5), with the 
exception of  angiogenin, endothelin 1, PDGF-AB/BB and angiostatin/plasminogen that were 
upregulated (normalized values > 1.5) and endoglin, HB-EGF, IL-8, Leptin, MIP 1a, and PDGF-
AA and prolactin and TIMP-4 were downregulated (normalized values < 0.5). 
 
 
Figure 12. The normalized expression of (A) pro-angiogenic factors and (B) anti-angiogenic factors when MCF-7 
where encapsulated in glycated collagen gels relative to non-glycated collagen gels. The closely dashed and widely 








In this study, only three pro-angiogenic factors were over expressed by MCF-7 cells 
encapsulated in the stiffer matrix (angiogenin, endothelin-1, and PDGF-AB/BB), whereas, 
multiple pro-angiogenic factors were upregulated by invasive cancer cells (activin A, 
amphiregulin, artemin, IL-1β, persephin, uPA, and VEGF) (in Chapter 4). Amphiregulin, which is 
an EGF-related peptide, was overexpressed by highly aggressive MDA-MB-231 cancer cells 
encapsulated in stiffer matrices, but not by the non-aggressive MCF-7 cells encapsulated in stiffer 
matrices. This is consistent with other studies where the frequency and levels of amphiregulin 
expression are generally higher in invasive breast tumors than in localized carcinoma or in normal 
breast tissue [51]. Moreover, MDA-MB-231 exhibited no change in the expression of anti-
angiogenic signals with increasing stiffness. On the other hand, MCF-7 encapsulated in stiffer 
matrices grossly over-expressed angiostatin, a specific angiogenesis inhibitor produced by tumors 
that blocks tumor angiogenesis and inhibits metastatic and primary tumor growth [52]. While 
VEGF-C was only expressed by the cells in the stiffer matrices, this is consistent with other studies 
where VEGF-C in MCF-7 tumors strongly encourages the growth of tumor-associated lymphatic 
vessels but unlike VEGF, does not have any significant effects on tumor angiogenesis [53]. In 
comparison to the highly invasive cell line, non-invasive MCF-7 cells did not exhibit a significant 
alteration in the angiogenic signaling as a function of matrix stiffness. These results are in 
agreement with the trend observed in earlier 2D studies whereby substrate stiffness-dependent 




Chapter 6: Effect of Mechanotransduction Inhibitors on Angiogenic Activity 
Introduction 
In Chapter 4, we observed formation of actin-based protrusion of plasma membranes when 
MDA-MB-231 cells were encapsulated within the stiffer gels. On the other hand, no difference in 
morphology or cytoskeletal arrangement was observed in case of MCF-7 cells. This observation 
along with the angiogenesis results discussed in Chapter 4 suggests that differential secretory 
responses of MDA-MB-231 cells may be partly related to the cell contractility or cytoskeletal 
reorganization. Previous studies demonstrated that the change in mechanical properties of the 
microenvironment increase integrin clustering and recruitment of focal adhesion proteins leading 
to cytoskeletal reorganization [24, 54, 55]. These changes result in activation of the Rho/ROCK 
pathways. In an earlier study, Rho associated kinase (ROCK) inhibition decreased substrate 
stiffness-dependent increase in proliferation and migration of cells as well as significantly reduced 
the release of VEGF [30]. This suggests that the signaling pathways and their effect on cytoskeletal 
reorganization may have an important function in tumor angiogenesis.   
 To study the effect of inhibiting mechanotransduction pathways on the pro-angiogenesis 
release of cancer cells with invasive phenotype, three inhibitors, each affecting the mechanical 
signaling pathway were added to the cells. Since it was shown earlier that aggressive cancer cells 
in stiff matrices exhibited an increase in pro-angiogenesis signaling, the inhibitors were added to 
MDA-MB-231 cells in stiff matrices, only. Specifically, Y-27632, Blebbistatin, and Cytochalasin 
D inhibitors were used. Y-27632 is a widely used Rho/ROCK inhibitor that binds to the catalytic 
site of these kinases thereby inhibiting their activity and the formation of stress fibers [56]. 
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Blebbistatin is a myosin II inhibitor that binds to the myosin-ADP-Pi complex and interferes with 
the phosphate release process, thereby preventing proper crosslinking of actomyosin [57]. 
Cytochalasin D is a widely used actin inhibitor that inhibits both the polymerization and 
depolymerization of actin subunits by binding to actin filament ends [58]. The angiogenesis release 
profile from cells incubated with the different inhibitors was assessed, and the effect of the 
inhibitors on cell viability was also determined.  
Methods 
Inhibition of Mechanotransduction Pathways 
Cancer cells were embedded into collagen gels at a density of 12.5 x 104 cells/gel and 
incubated in serum-free media for 48 hours at 37℃ and 5% CO2. Following which, serum-free 
media containing either 10µM of Y-27632, 50 µM of Blebbistatin, or 1µM of Cytochalasin D, 
inhibitors targeting the mechanotransduction pathway, were added to the cells embedded into stiff 
collagen matrices. The cells were incubated with the different inhibitors for 48 hours at 37℃ and 
5% CO2. Cells incubated in serum-free media without any inhibitors served as the control. The 
cell viability was assessed using AlamarBlueTM Cell Viability Reagent for 3.5 hours, and the 
fluorescence intensity was measured at excitation/emission wavelengths 570/595 nm to ensure that 
the inhibitors were not toxic to the cells. Following incubation for 48 hours, the media was 
collected, concentrated, and the profile of the released angiogenic factors was assessed via 
Proteome ProfilerTM Human Angiogenesis Array from R&D Systems as described earlier.  
Results 
After 48 hours of incubation with the inhibitors, the serum-free media was collected and 
assessed for the released angiogenic factors. Figure 13 shows the normalized signal intensities of 
the factors released by cells from gels in presence of inhibitors with respect to those released in 
the absence of inhibitors. Y-27632, downregulated the expression of multiple molecules including 
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angiogenin, angiopoietin-1, amphiregulin, artemin, FGF acidic, GDNF, GM-CSF, IGFBP-1, IL-
1β, MIP-1a, MMP-8, PD-ECGF, PDGF-AA, PDGF-AB/BB, uPA, VEGF (pro-angiogenic factors) 
(Fig 13). On the other hand, in the presence of Blebbistatin and Cytochalasin D, the expression of 
multiple pro-angiogenic molecules were upregulated.  
 
Figure 13. Effect of mechanotransduction inhibitors on pro-angiogenic signaling of MDA-MB-231 encapsulated in 
stiff (250 mM) collagen gels. The normalized expression of pro-angiogenic factors when MDA-MB-231 cells were 
incubated with 10µM of Y-27632, 50 µM of Blebbistatin, or 1µM of Cytochalasin D relative to cells incubated without 
inhibitors. The closely dashed and widely dashed lines corresponds to the relative expression of 0.5 and 1.5, 
respectively.  
The cell viability was tested to assess whether the alteration in angiogenic signaling is due 
to the cytotoxicity of the pharmacological inhibitors. However, no difference in the viability of the 
cells incubated in the presence of different inhibitors was observed when compared to those 
incubated in the absence of inhibitors (Fig 14). This suggests that differential expression of 
angiogenesis-related factors by MDA-MB-231 in the presence of pharmacological inhibitors can 




Figure 14. The cell viability of MDA-MB-231 cells in stiff (250 mM) matrices incubated with and without inhibitors. 
Inhibitors did not affect cell viability. Error bar S.E.M (N=3). 
Discussion 
The local interactions between F-actin, myosin filaments, and various crosslinking proteins 
govern force generation, dynamics, and reorganization of the intracellular cytoskeleton. The 
cytoskeleton is responsible for many essential cellular functions including migration, adhesion, 
and mechanotransduction (59). Our study demonstrated that ROCK inhibitor, Y-27632, 
downregulated the expression of the pro-angiogenic factors, suggesting the involvement of ROCK 
signaling pathway in the stiffness-dependent pro-angiogenic signaling of MDA-MB-231 cells. On 
the contrary, Blebbistatin and Cytochalasin D upregulated the expression of different pro-
angiogenic molecules. Although this was somewhat unexpected, we anticipate that different 
mechanisms by which actin filament disruptors and myosin inhibitor affect the cytoskeleton may 
play a role in the angiogenic activity of the cancer cells. Y-27632 is a specific inhibitor of ROCK 
activity. As a major effector of RhoA, ROCK modulates actin cytoskeleton organization, stress 
fiber formation, and smooth muscle contraction via phosphorylation of myosin light chain (MLC) 
and LIM kinase (LIMK) and has been associated with matrix-stiffness induced 
































essential for stress fiber formation and various cellular functions (30). Blebbistatin selectively 
inhibits non-muscle myosin II in an actin-detached state (57) thereby inhibiting ATP-binding 
required for motor activity and actin cross-linking, independently of MLC phosphorylation (60). 
On the other hand, Cytochalasin D inhibits actin polymerization and induces depolymerization of 
actin filaments (59). The data above shows that neither the inhibition of non-muscle myosin II nor 
the inhibition of actin polymerization govern the pro-angiogenic signaling of MDA-MB-231 cells. 
Instead, this study shows that the angiogenic activity of the breast cancer cells is dependent on the 




Chapter 7: Conclusion 
 In this study, collagen hydrogels of varying stiffness were fabricated using a non-enzymatic 
glycation approach and characterized. Highly invasive breast cancer cells, MDA-MB-231, were 
encapsulated in soft (non-glycated) and stiff (glycated) matrices. Stiffer microenvironments 
resulted in an increase of pro-angiogenic signaling and the expression of many angiogenesis-
related factors not expressed in soft matrices. The change in stiffness, however, did not alter the 
anti-angiogenic signaling by the aggressive cancer cells. Furthermore, the bioactivity of the 
released angiogenesis factors was assessed through the proliferation of HUVECs cells. The 
observed increase in their proliferation in presence of conditioned media from stiffer gels was not 
statistically significant. We also investigated whether the stiffness-dependent secretory activity of 
breast cancer cells can be correlated to their aggressive phenotype. Towards this, breast cancer 
cells of low invasiveness were encapsulated in soft and stiff collagen gels, and their angiogenic 
signaling was minimally altered. This reveals differential responses of breast cancer cells 
displaying varying degrees of invasiveness to changes in stromal stiffening. Furthermore, the 
increase in pro-angiogenic activity in cancer cells subject to increased substrate stiffness indicates 
the existence of a mechanotransduction pathway that has not only been shown to regulate cell 
behavior but also suggests its potential regulatory role in angiogenesis. Highly aggressive breast 
cancer cells in stiff matrices were incubated with three different inhibitors. Y-27632, ROCK 
inhibitor, significantly interrupted the pro-angiogenic release, while Blebbistatin, myosin II 
inhibitor, and Cytochalasin D, actin polymerization inhibitor, did not inhibit the release of pro-
angiogenic factors by the cancer cells. This suggests that the angiogenic activity of breast 
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cancer cells is dependent on the activation of Rho/ROCK pathway, and interfering with this 

















Chapter 8: Motivation and Objectives 
At initial diagnosis with breast cancer, up to 5% of patients present with distal metastases, 
and an additional 10-15% develop metastases within three years of diagnosis [61]. Metastasis is 
the spread of cancer cells from the primary tumor location to surrounding and distant tissues and 
is responsible for 90% of cancer deaths. Bone metastasis is characterized by severe pain, impaired 
mobility, fractures, spinal cord compression, bone marrow aplasia and hypercalcemia and results 
in an average survival period of 19-25 months upon metastasis from breast cancer [63]. Once 
metastasis occurs, it becomes hard to control and cure the disease, and treatment becomes more 
focused on slowing disease progression and alleviating pain. Therefore, it is important to acquire 
a better understanding of bone metastasis in order to develop effective treatments for metastasized 
tumors. 
In order for the cancer cells to thrive in the foreign microenvironment and progress to form 
lesions and proliferate, the extravasated tumor cells need to manipulate and recruit the resident 
host cells in the bone marrow, namely osteoblasts and osteoclasts. They do so by secreting 
osteolytic factors that directly stimulate bone resorption by osteoclasts and indirectly promoting 
osteoclastogenesis via upregulation of RANKL signaling by osteoblasts [11]. This results in the 
increased osteolysis that is characteristic of bone metastasis from primary breast tissue. Tumors 
also affect stromal cells in the bone marrow that can differentiate into osteoblasts, osteoclasts, or 
adipose cells [11]. Furthermore, as mentioned earlier, tumor cells also secrete angiogenic factors 
that allow blood vessel formation to occur to support the ever-growing demand of more nutrients 
and oxygen by the proliferating and growing tumor.  
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The ability to identify molecular factors that influence the establishment and progression 
of tumor cells in bone tissue is of key importance in the development of novel methods for the 
treatment of bone metastasis. Although animal models provide an in vivo model for metastasis 
research and the understanding of microenvironment-mediated pathways, they also pose a series 
of complexities, such as uncontrolled variables, lack of human physiology, and variability across 
different models [63]. In vitro models, on the other hand, can either be oversimplified or highly 
complex, yet expensive and require specially equipped laboratories.  
Two-dimensional (2D) systems, although cost efficient and simple, fail to capture the 
dynamic interactions between the cells and their microenvironment which undergoes constant 
remodeling by the cells and affects cell behavior. As a result, testing done on 2D models cannot 
be indicative of results in a more complex in vivo system, such as the human body [63].  In recent 
years, several attempts have been made to develop three-dimensional (3D) models for studying 
bone metastasis. These models often combine host cells, mesenchymal stem cells or osteoblasts, 
with tumor cells in artificial scaffolds. While these models demonstrate a significant improvement 
over 2D systems, they lack natural bone microenvironment or well-controlled spatial distribution 
of cancer cells [63]. As a result, these 3D systems limit our ability to effectively study early stages 
of metastasis and bone microenvironment interactions with the invading tumor cells. Because bone 
metastasis is still incurable and poorly understood, there is a pressing need for a cost-efficient, yet 
innovative, in vitro model complex enough to simulate the tumor environment and mechanical 
characteristics of in vivo biology for the development and screening of new therapeutic drugs.  
We hypothesize that utilization of decellularized ECM (dECM), that preserves the natural 
composition and structure, will permit bioprinting physiologically relevant 3D model of breast 
cancer metastasis to bone.  Thus, this study is aimed at generating structurally preserved bone-like 
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microenvironments that permit the understanding of cancer behavior during the early stages of 
metastasis. The research conducted in this work addressed the following two objectives:  
Objective 1: Characterize dECM obtained from osteogenesis-differentiated mesenchymal 
stem cells (MSCs) 
Bone marrow-derived human MSCs were osteogenically differentiated for 21 days. The 
generated matrices were decellularized and characterized to determine their composition.  
 
Objective 2: Test effect dECM and tumor interaction on the behavior of highly aggressive 
cancer cells. 
MDA-MB-231 cells were seeded on osteogenic differentiated and undifferentiated dECM. 
Their cell proliferation was assessed. Additionally, the inhibitory effect of chemotherapy 




Chapter 9: Characterization of dECM 
Introduction 
The bone microenvironment consists of a variety of cells including endothelial, immune, 
and hematopoietic and bone marrow stem cells [64]. However, the extracellular matrix (ECM), 
produced by osteoblasts, makes up the bulk of the bone’s dry weight. Osteoblasts are bone cells, 
derived from the differentiation of mesenchymal stem cells (MSCs), that play a role in bone 
remodeling, bone mineralization, as well as the production of ECM components [65, 66, 67]. Bone 
matrix consists of organic and mineralized inorganic components. The mineralized inorganic part 
of the ECM consists of calcium and phosphate in the form of hydroxyapatite crystals that provide 
the bone tissue with specific properties, such as rigidity and hardness [64]. Meanwhile, the organic 
component of the ECM encompasses three major biomolecules: fibrous proteins, glycoproteins, 
and proteoglycans.  
Collagen fibers account for nearly 90% of the proteins in bone ECM, with collagen type I 
as the most common form. In addition to its role in biochemical signaling, the collagen matrix 
provides the bone with strength and stability as well as a scaffold for cells to attach and form bone 
tissue [65, 66, 68]. Collagen fibers are composed of densely packed molecules with a triple helical 
structure that arrange in a directional manner reflecting the cell’s orientation [65, 69, 70, 71]. The 
properties provided by the organization of these fibers dictate many cellular behaviors, such as 
proliferation, migration, and differentiation [65, 72, 73].  
Glycoproteins within the matrix, specifically fibronectin, facilitate cell-matrix interaction, 
namely cell adhesion, migration, and differentiation [65, 74]. In the bone, fibronectin is produced 
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by osteoblasts and has been shown to induce the osteogenic differentiation of MSCs [65, 76]. 
Additionally, fibronectin mediates the formation of collagen fibers through its collagen binding 
domain [65, 74].  
Proteoglycans are a major component of the ECM and are essential for regulated bone 
matrix formation. They modulate cell signaling through the binding of proteins to either enhance, 
diminish, or inhibit their signal, or by preventing the degradation of proteins [2, 69].  Proteoglycans 
consist of side sugar chains, glycosaminoglycans (GAGs), that are bound to a core protein. GAGs 
play an important role in the bone matrix by regulating the availability and activity of many 
osteoclastic and osteogenic factors [77].  
 To study bone metastasis of breast cancer using naturally derived bone microenvironments, 
bone-marrow derived MSCs were differentiated into osteoblasts. Successful osteogenic 
differentiation was confirmed by detection of alkaline phosphatase activity and extracellular 
calcium deposits via Alizarin Red S staining. Further, the deposited ECM by osteoblasts was 
decellularized and characterized to determine if successful deposition of key bone matrix 
components occurred. Specifically, the decellularized ECM (dECM) was examined to verify the 
deposition of collagen, fibronectin, and sulfated glycosaminoglycans.    
Methods 
Osteogenic Differentiation of MSCs 
Mesenchymal stem cells (MSCs), derived from bone marrow, were purchased from 
American Type Culture Collection (ATCC) and cultured in Dulbecco’s Modified Eagle Medium 
(DMEM, Gibco, NY) supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) 
penicillin-streptomycin at 37℃ and 5% CO2. Cells were detached from flasks using 0.25% 
Trypsin-EDTA, and resuspended MSCs were seeded in 6 well plates at a density of 5 x 104 
45 
 
cells/well. The cells were cultured in complete DMEM media for 72 hours, or until they reached 
confluency. Following which, differentiation media consisting of Stem Pro 
Osteocyte/Chondrocyte Differentiation Basal Medium (Gibco, NY), 10% (v/v) StemPro 
Osteogenesis Supplement (Gibco, NY), and 1% (v/v) penicillin-streptomycin was added to the 
cells and replaced every 3 days for a total differentiation period of 21 days. MSCs cultured for 21 
days in complete DMEM media served as the control. 
Confirmation of Osteogenic Differentiation 
Osteogenic differentiation was confirmed using Alkaline Phosphatase test and Alizarin 
Red S Staining. Alkaline phosphatase test was carried out after 9 days of differentiation. Briefly, 
the cells were fixed with 1:1 acetone:methanol at -20℃ for a maximum of 90 seconds to avoid 
inactivation of alkaline phosphatase. The fixed cells were then rinsed with washing buffer 
consisting of 0.05% Tween 20 in DPBS for 45 seconds and incubated with alkaline dye mixture 
at room temperature for 30 minutes in the dark. To prepare the alkaline dye mixture, Fast Blue RR 
Salt pre-weighed capsule (Sigma Aldrich, MO) was dissolved in 48 mL of distilled water to 
prepare diazonium salt solution. 2 mL of Naphthol As-MX Phosphate Alkaline solution was added 
to the diluted diazonium salt solution. After incubation, the cells were washed with distilled water 
for 3 minutes, and DPBS was added to the wells. The cells were imaged using Zeiss Axio Observer 
A1 microscope with integrated CCD camera.  
Alizarin Red S Staining was carried out after 21 days of differentiation. The cells were 
fixed with 1:1 acetone:methanol solution at -20℃ for 20 min and washed with DPBS. 2% (v/v) 
Alizarin Red S staining solution was added to the fixed cells and incubated at room temperature 
for 45 min in the dark. The staining solution was prepared by dissolving Alizarin Red S in distilled 
water, and the pH was adjusted with 1 M HCl to achieve a pH range of 4.1-4.3. After 45 minutes, 
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the cells were washed four times with distilled water and replenished with DPBS for imaging.  
Deposition and Decellularization of dECM 
MSCs were seeded in Lab-Tek chamber slides at a density of 1.5 x 104 cells/chamber and 
cultured until confluency with complete DMEM medium. After confluency, the cells were cultured 
in osteogenesis differentiation media or normal DMEM media. After 21 days, the cells were 
treated with 0.5% Triton-X-100 (Sigma-Aldrich, MO) in 20 mM ammonium hydroxide (NH4OH, 
Fisher Scientific, NJ) for 10 minutes at 37℃, as described earlier [78]. The wells were then washed 
with DPBS for 5 minutes and treated with 200µg/mL DNase I, RNase-Free (OPTIZYME, 
FisherBioReagents), for 60 minutes at 37℃. Following which, the wells were rinsed with DPBS 
for 5 minutes and left to air dry overnight to allow for good visualization of dECM. Phase contrast 
images of the dried ECM were then captured.  
Immunostaining 
Immunofluorescence staining was carried out as described previously [78]. The 
decellularized ECM (dECM) was fixed using a 1:1 methanol:acetone solution at -20℃ for 20 
minutes and washed once with DPBS. The fixed dECM was blocked with 5% BSA for 1 h at room 
temperature on an orbital shaker and washed once with DPBS. The samples were then incubated 
overnight with COL1A1 antibody (Santa Cruz biotechnology) and monoclonal anti-fibronectin 
antibody (Sigma Aldrich, MO). The samples were rinsed once with DPBS and incubated with 
secondary antibody for 1h at room temperature. Following which the samples were washed, and 
confocal images of collagen and fibronectin in the dECM were captured.  
Quantification of Deposited Collagen in dECM 
To determine the concentration of deposited collagen in dECM, a Soluble Collagen Assay 
Kit (Cell BioLabs, CA) was utilized. Briefly, dECM samples in 6 well plates were incubated with 
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0.5mg/mL of pepsin (Sigma-Aldrich, MO) solution in 0.5M acetic acid overnight at 4℃. 100µL 
duplicates of digested dECM samples and collagen standards were transferred to the wells of a 96 
well plate and allowed to dry at 37℃ overnight. Sirius Red reagent was added to the wells at room 
temperature for 1 h on an orbital shaker to stain the collagen, and the stained samples were washed 
with 5% acetic acid and incubated with an extraction solution for 30 minutes. The collagen 
concentration was determined by measuring the absorbance using SpectraMax M3 Multi-Mode 
Microplate Reader at a wavelength of 550 nm.  
Quantification of Sulfated Glycosaminoglycans 
The amount of deposited sulfated glycosaminoglycans (GAGs) in the dECM was 
determined using Glycosaminoglycans Assay Kit (Chondrex, Inc., WA). First, dECM samples 
were digested with papain extraction reagent for 3 h at 37℃ to extract the sulfated GAGs. 100 µL 
duplicates of digested dECM, along with standards, was added to 96 well plates. 1,9 
Dimethylmethylene Blue (DMB) dye solution was added to the samples, and the absorbance was 
measured using BioTek Eon Microplate reader at a wavelength of 525 nm to determine the 
concentration of GAGs in the samples.  
Results and Discussion 
Before isolating the ECM from the osteogenic differentiated cells, it was important to first 
determine that the differentiation process used was successful. Undifferentiated mesenchymal 
stem cells (MSCs) display weak alkaline phosphatase (AP) activity, whereas differentiated 
osteoblasts show very high AP activity. As shown in Figure 15A, insoluble precipitates formed 
after 9 days of differentiation, confirming alkaline phosphatase activity at those sites, but were not 
visible in undifferentiated MSCs (Fig 15B). Moreover, differentiated osteoblasts exhibit extensive 
extracellular calcium deposits  during bone formation, while undifferentiated MSCs do not deposit 
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calcium. Using Alizarin Red S, calcium deposits stain bright orange-red as shown in the image of 
differentiated MSCs in Figure 15C, whereas undifferentiated cells were colorless (Fig 15D). 
Together, alkaline phosphatase activity and calcium deposits indicate the successful differentiation 
of MSCs into osteoblasts.  
 
Figure 15. Confirmation of osteognic differentiation of MSCs. Alkaline phophatase test detected insolube precipitates 
indicating AP activity in (A) differentiated MSCs, but did not detect any enzyme activity in (B) undifferentiated 
MSCs. Scale bar corresponds to 200µm. Alizarin Red S staining was performed to check for calcium deposits. (C) 
Differentiated MSCs stained a bright red indicating the presence of calcium deposits, while (D) undifferentiated MSCs 
remained colorless, indicating no extracellular calcium depostition. Scale bar corresponds to 100µm.   
The methods utilized in this study led to cellular deposition of ECM, which was structurally 
preserved during the decellularization process. Figure 16 shows phase contrast images of the dried 





MSC-derived osteoblasts show a more visibly dense network (Fig 16A) than what was deposited 
by undifferentiated MSCs (Fig 16B).  
 
Figure 16. Phase contrast images of deposited ECM after decellularization of (A) differentiated MSCs and (B) 
undifferentiated MSCs. Scale bar corresponds to 500µm. 
Since the differentiated MSCs appeared to deposit a denser ECM network than the layer 
deposited by undifferentiated MSCs, the decellularized matrix was characterized to determine the 
difference in the amount of secreted ECM components. For this purpose, the dECM was stained 
for collagen and fibronectin, two of the major structural proteins of the extracellular matrix. 
Confocal images in Figure 17 of stained dECM showed that collagen and fibronectin were 





Figure 17. Confocal images of immunofluorescence stain of collagen and fibronectin in decellularized ECM of 
undifferentiated and differentiated MSCs. Immunostaining of collagen showed less deposition by (A) undifferentiated 
MSCs compared to (B) differentiated osteoblasts. Immunostaining of fibronectin in dECM also showed less deposition 
by (C) undifferentiated MSCs compared to (D) differentiated osteoblasts. Scale bar corresponds to 170 µm.   
 To further demonstrate the visible disparity in protein deposition in the dECM of 
osteogenic differentiated and undifferentiated MSCs, the concentration of collagen was 
quantitatively determined. The decellularized matrix of differentiated osteoblasts contained a 
greater concentration of collagen in comparison to the undifferentiated MSCs (Fig 18A). 
Moreover, the concentration of deposited proteoglycans was assayed. Osteoblasts secreted more 
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sulfated glycosaminoglycans into the ECM than MSCs (Fig 18B). The increase in, both, collagen 
and sulfated GAGs was statistically insignificant (p-value > 0.05).  
 
Figure 18. Quantification of the concentration of deposited (A) collagen and (B) sulfated glycosaminoglycans in the 
decellularized matrices of differentiated osteoblasts and undifferentiated MSCs. Error bar S.E.M (N=3). 
The results shown above indicate that the methods used in this section allow the production 
of bone-like environments containing critical components of the extracellular matrix, such as 
collagen, fibronectin, and GAGs. More importantly, this provides a model that can replicate the in 
vivo bone environment that breast cancer cells invade during the initial stages of lesion formation. 
Bone metastatic cancer has been shown to change the production and orientation of collagen, 
thereby disrupting proper bone structure and function. Specifically, tumor cells result in an 
increased deposition of dense, misaligned collagen fibers at the site of invasion resulting in bone 
weakness [65]. Furthermore, fibronectin production is also altered by cancer cells, which release 
signals that drive native cells to produce a highly unorganized matrix of thick, dense fibronectin 
















































Chapter 10: Effect of dECM on Aggressive Breast Cancer Cells 
Introduction 
The bone matrix is under constant remodeling, with a balance between degradation of ECM 
components by osteoclasts or secretion by osteoblasts, to maintain an optimum bone density and 
strength [64, 65]. However, due to bone metastasis, these normal processes are disrupted. Tumor 
cells stimulate osteoclasts to resorb part of the ECM [11] and recruit osteoblasts such that they 
deposit collagen type I and other ECM components in a highly disordered manner leading to a stiff 
and unorganized matrix [65]. This change in matrix structure promotes tumor growth and invasion.  
In this study, the impact of bone matrix on the behavior of highly aggressive breast cancer 
is investigated. Previous studies showed that the presence of a mineralized matrix enhances cancer 
cell adhesion and proliferation [81]. Furthermore, recent evidence suggests that the tumor 
microenvironment plays a role in the cell’s resistance to drugs [82]. Here, the effect of osteoblast-
derived ECM on the proliferation of MDA-MB-231 cancer cells was studied. Moreover, the 
efficacy of chemotherapeutic drug, 5-fluorouracil, on the cells was tested.  
Methods 
Proliferation of Aggressive Breast Cancer Cells on dECM 
dECM of osteogenic differentiated and undifferentiated MSCs was generated in 48 well 
plates as described earlier. MDA-MB-231 breast cancer cells were seeded on dried dECM at a 
density of 2 x 104 cells/well and incubated in complete RPMI media for 72 hours.  Cell seeded on 
tissue culture plate (TCP) with no dECM served as the control. Cell proliferation was assessed
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using AlamarBlue Cell Viability Reagent. The proliferation of cancer cells on dECM was 
expressed as percent growth over the control. 
 Determining Change in Efficacy of Chemotherapeutic Agent 
 MDA-MB-231 cells were again seeded on differentiated and undifferentiated dECM in 48 
well plates at a density of 2 x 104 cells/well and incubated in complete RPMI medium for 24 hours. 
Cancer cells seeded on tissue culture plate (TCP) served as the control. After the cells were 
established on the dECM, 50 mg/mL of 5-fluorouracil (5-FU, Sigma-Aldrich, MO) stock solution 
in dimethyl sulfoxide (DMSO, Sigma-Aldrich, France) was diluted in RPMI medium to achieve 
varying concentrations (0µg/mL-50µg/mL) and added to the cells. To prevent any confounding 
effects, DMSO was maintained at a concentration of 0.1% in the final drug solutions. The cells 
were replenished with fresh media containing 5-FU 48 h after initially introducing the drug and 
again at 72 h. The cell viability was measured after 96 hours of incubation with the 
chemotherapeutic agent.   
Results and Discussion 
 The effect of dECM from differentiated osteoblasts and undifferentiated MSCs on the 
proliferation of highly invasive breast cancer cells was determined. MDA-MB-231 cancer cells 
were seeded on dECM and TCP (control), and their growth was measured after 72 hours relative 
to the control. Although not statistically significant (p > 0.05), cancer cells seeded on osteoblast-
derived dECM exhibited an increase in proliferation compared to undifferentiated MSC derived 
dECM (Fig 19). The increase in proliferation of cancer cells seeded on bone dECM compared to 
no ECM was observed in other studies where cells were seeded on porous poly(lactide-co-
glycolide) (PLG) scaffolds containing nanoparticles with hydroxyapatite [83]. Another study 
found that the mineralization of porous poly vinyl alcohol (PVA) scaffolds resulted in the adhesion 




Figure 19. Proliferation of MDA-MB-231 cancer cells on decellularized ECM of differentiated osteoblasts and 
undifferentiated MSCs. Cell growth was normalized relative to cells seeded on wells with no ECM. Error bar S.E.M 
(N=3).   
Recent evidence suggests that the tumor environment not only regulates the behavior of 
cancer cells and promotes tumor progression, but it also is involved in the drug resistance 
properties acquired by cancer cells [82, 84]. Environment-mediated drug resistance is believed to 
be a result of chemical and mechanical cues as well as the interaction of the tumor with stromal 
cells and interaction with the extracellular environment [82]. Therefore, to test the efficacy of 
chemotherapeutic agents in inhibiting tumor colonization of the bone microenvironment, MDA-
MB-231 cells were seeded on the decellularized matrices from osteoblasts and MSCs as well as 
TCP for comparison. The tumor cells were allowed to establish for 24 h in growth medium before 
being challenged with anti-cancer agents. Following attachment, the cells were treated with 
chemotherapy drug, 5-fluorouracil (5-FU). The concentration of the drug was varied from 0-50 
µg/mL. After 96 hours of incubation with the drug, the cell viability of the cancer cells was 
measured. Cancer cells seeded on the dECM of both osteoblasts and MSCs exhibited a significant 
decrease in sensitivity (p-value < 0.05) to the drug in comparison to cells that were seeded on TCP 


























in the concentration of chemotherapy drugs was required to achieve a comparable reduction in cell 
viability of MDA-MB-231 cells seeded on silk-based matrices [84]. Moreover, a study that 
involved the co-culture of MDA-MB-231 cells with human osteoblast-like cells exhibited a greater 
viability when treated with the anti-cancer drug Paclitaxel compared to cancer cells cultured alone 
[82].  
 
Figure 20. Effect of osteoblast- and MSC-derived ECM on the viability of MDA-MB-231 cancer cells after incubation 
with varying concentrations of chemotherapeutic agent, 5-fluorouracil. The viability was normalized with respect to 
cells incubated in similar environments with no drug. Error bar S.E.M (N=3). *p-value<0.05 with respect to cells 































Chapter 11: Conclusion 
In this study, mesenchymal stem cells (MSCs) were successfully differentiated into 
osteoblasts. Decellularized ECM from differentiated osteoblasts showed a greater deposition of 
collagen, fibronectin, and sulfated GAGs than MSC-derived matrices. The generated bone 
matrices were seeded with highly invasive breast cancer cells to study the effect of 
microenvironments on cancer cell behavior. Cancer cell proliferation increased when seeded on 
the bone matrices. Additionally, MDA-MB-231 cancer cells were challenged with 5-fluorouracil, 
a chemotherapeutic agent. Cells seeded on undifferentiated MSC- and differentiated MCS-derived 
matrices showed a significant reduction in the efficacy of the drug relative to cells seeded on wells 
with no matrices, suggesting an important role of the microenvironment, not only on cancer cell 




Chapter 12: Future Studies 
The work completed in part 1 of this thesis highlighted the role of matrix stiffness on the 
angiogenic activity of breast cancer cells through the release of angiogenesis-related factors. 
Future studies should include a 3D model of varying stiffness that houses both endothelial cells 
and cancer cells to study the direct effect of matrix compliance on the bioactivity of the released 
angiogenic factors. We predict that the endothelial cells would migrate towards the cancer cells in 
an attempt to form lumen-like structures due to the recruiting angiogenic signals released by the 
tumor cells. This model could potentially serve as an engineered tumor microenvironment that can 
be used in drug screening prior to drug testing trials on animals.  
The second part of the thesis focused on creating a bone-like environment to better 
understand bone metastasis of breast cancer. The current work demonstrated that the osteogenic 
differentiation of MSCs resulted in the deposition of critical components of bone extracellular 
matrix. Further, it showed preliminary testing of generated dECM on the behavior of breast cancer 
cells. Taken together, the studies in parts 1 and 2 demonstrate that a matrix consisting of 
physiologically relevant properties, including both composition and stiffness, can be used to 
characterize the aggressive behavior of malignant breast cancer cells. Although this work is a step 
in the right direction, an in-vitro model is needed to capture the tumor cell-extracellular interaction. 
For this purpose, a bioprinted 3D bone metastasis model consisting of breast cancer cells and 
osteoblast-derived ECM as well as relevant variations in stiffness will be considered. Alginate, a 
naturally-derived polymer, is a suitable material to provide the structural support needed in this
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model due to its low cost, biocompatibility, and ease of crosslinking as well as its widely used 
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